Cambridge-based CN Bio has launched PhysioMimix Core, an organ-on-a-chip system designed to streamline drug development workflows by integrating multiple experimental configurations within a single microphysiological platform. The release marks a significant development in reducing animal model dependency whilst improving clinical translation of preclinical data.

Scalable architecture addresses workflow flexibility

The PhysioMimix Core represents the first organ-on-a-chip solution to deliver validated performance across single-organ, multi-organ and higher-throughput configurations within one system. The platform supports screening of up to 288 samples simultaneously, enabling researchers to scale experimental designs as studies evolve from preliminary investigations through to comprehensive drug development programmes.

Built upon over a decade of organ-on-a-chip expertise, the system maintains CN Bio’s tubeless microfluidic engineering to minimise contamination risks and reduce daily maintenance requirements. Recirculating media and adjustable flow rates enable long-term studies including repeat dosing experiments and chronic disease modelling, whilst providing sufficient material recovery for multi-omics analysis.

The technology has gained recognition from the US Food and Drug Administration and is currently deployed by pharmaceutical companies internationally, supported by validated protocols, consumables and organ model kits.

Regulatory evolution drives adoption

Dr Paul Brooks, CEO of CN Bio, highlighted the shifting regulatory environment: “2025 has been an exciting year for the OOC sector, with legislative changes demonstrating a distinct shift towards new approach methodologies (NAMs) and allowing drug developers the flexibility to choose the most effective tools to advance their research.”

He added: “PhysioMimix Core directly addresses the gap in the market for a unified OOC system that is adaptable across the entire drug discovery and development pipeline. We work closely with regulators to anticipate the direction of the field, and this launch represents our focus on streamlining adoption and ensuring our customers stay ahead of that curve.”

Technical integration enhances usability

Sung Lee, Director of Product Management at CN Bio, emphasised the platform’s design philosophy: “PhysioMimix Core is a bold next step for the brand. By combining the strengths of all our existing systems into one intuitive platform, we’ve created a solution that delivers physiological precision with ease-of-use.”

The system maintains full compatibility with existing PhysioMimix accessories and protocols, enabling seamless integration into established laboratory workflows whilst providing researchers with expanded experimental capabilities through its modular architecture.

For more information, visit: https://cn-bio.com/physiomimix-core

Digital issue: Please click here for more information

Dr Paul Brooks,
CEO of CN Bio

Sung Lee, Director of Product
Management at CN Bio